CN203625386U - Kit for separating and culturing umbilical cord mesenchymal stem cells - Google Patents
Kit for separating and culturing umbilical cord mesenchymal stem cells Download PDFInfo
- Publication number
- CN203625386U CN203625386U CN201320735171.XU CN201320735171U CN203625386U CN 203625386 U CN203625386 U CN 203625386U CN 201320735171 U CN201320735171 U CN 201320735171U CN 203625386 U CN203625386 U CN 203625386U
- Authority
- CN
- China
- Prior art keywords
- umbilical cord
- stem cells
- mesenchymal stem
- separating
- cord mesenchymal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000003954 umbilical cord Anatomy 0.000 title claims abstract description 55
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 43
- 238000012258 culturing Methods 0.000 title abstract 3
- 108010010803 Gelatin Proteins 0.000 claims abstract description 36
- 229920000159 gelatin Polymers 0.000 claims abstract description 36
- 239000008273 gelatin Substances 0.000 claims abstract description 36
- 235000019322 gelatine Nutrition 0.000 claims abstract description 36
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 36
- 238000013016 damping Methods 0.000 claims description 58
- 239000012530 fluid Substances 0.000 claims description 58
- 238000012360 testing method Methods 0.000 claims description 35
- 239000002504 physiological saline solution Substances 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 238000000926 separation method Methods 0.000 abstract description 23
- 239000007853 buffer solution Substances 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 24
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 17
- 239000003292 glue Substances 0.000 description 16
- 239000012679 serum free medium Substances 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 10
- 230000008569 process Effects 0.000 description 9
- 102000029816 Collagenase Human genes 0.000 description 8
- 108060005980 Collagenase Proteins 0.000 description 8
- 229930182555 Penicillin Natural products 0.000 description 8
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 8
- 229960002424 collagenase Drugs 0.000 description 8
- 229940049954 penicillin Drugs 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 7
- 108090000145 Bacillolysin Proteins 0.000 description 5
- 102000035092 Neutral proteases Human genes 0.000 description 5
- 108091005507 Neutral proteases Proteins 0.000 description 5
- 108010019160 Pancreatin Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000010297 mechanical methods and process Methods 0.000 description 5
- 230000005226 mechanical processes and functions Effects 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 229940055695 pancreatin Drugs 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000001644 umbilical artery Anatomy 0.000 description 5
- 210000003606 umbilical vein Anatomy 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101150022655 HGF gene Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102000002070 Transferrins Human genes 0.000 description 1
- 108010015865 Transferrins Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 210000002718 aborted fetus Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000012578 cell culture reagent Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229960004232 linoleic acid Drugs 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 238000007443 liposuction Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The utility model relates to a kit for separating and culturing umbilical cord mesenchymal stem cells. The kit for separating and culturing umbilical cord mesenchymal stem cells comprises a box body, wherein at least a buffer solution placing area, a gelatin placing area and a culture medium placing area are arranged in the box body. By adopting the kit provided by the utility model, the separation and culture of umbilical cord mesenchymal stem cells can be realized. The kit has the characteristics of simple structure and convenience in use, and facilitates the high-purity and high-efficiency separation and culture of umbilical cord mesenchymal stem cells.
Description
Technical field
The utility model relate to a kind of for separating of with cultivate the test kit of umbilical cord mesenchymal stem cells, belong to technical field of bioengineering.
Background technology
Mescenchymal stem cell is the multipotential stem cell being extensively present in reticular tissue and organ interstitial, there is good multiplication capacity and multi-lineage potential, under given conditions can be to functional cell differentiation such as scleroblast, chondrocyte, myocardial cell, hematopoietic cell, liver cells.Because MSCs convenient sources, is easy to separation, amplification in vitro and purifying, and after amplification, still can keep dryness going down to posterity, be therefore the desirable seed cell source of organizational project, genetically engineered and cell therapy.In addition, MSCs has powerful immunoloregulation function, has the feature of reduced immunogenicity in transplanting, in the treatment of autoimmune diseases such as hepatopathy etc. in whole latter stage disease in latter stage at end and systemic lupus erythematous, has broad application prospects.
The clinical experimental study having carried out at present confirms, in whole latter stage liver disease, MSCs transplants can obviously improve patient's liver function; And transplant after skin keratin cell is mixed with MSCs, can effectively extend the survival time of cutify and reduce the anti-Immunological diseases of allogeneic (graft vs host disease, GVHD).Research for MSCs immune regulation mechanism thinks, MSCs, mainly by paracrine action, produces panimmunity regulatory factor, acts on after immunocyte inducing immune tolerance, thereby the immune effect of performance regulation and control body.
In addition, by MSCs is carried out to genetic modification, the genes such as IFN β, EPO are imported in its genome, can obtain the functional cell of can be in vivo long-time this albumen of stably express or cytokine.The people such as Wu Zuze import the gene of HGF in MSCs, experiment in vivo and vitro confirms that people's marrow MSC of HGF gene transfection still maintains original propagation and differentiation capability, and to cell in vitro, immune response has stronger inhibition, therefore in transplanting, histoorgan there is larger potential using value (limit jasmine, Guo Zikuan, Ai Huisheng, Wang Hua, Meng Erhong, Wu Zuze, Wang Lisheng; HGF genetic modification strengthens the immunosuppressive action of mescenchymal stem cell; Institute of Military Medical Science Institute periodical; 2006,30 (4): 323-328).Just because of this, at present various countries all drop into a large amount of manpower and materials funds and carry out extensive research.But all research or treatment plan all must be based upon on the basis that q.s MSCs obtains, the technology volume of therefore setting up stable MSCs separation fast and effectively, amplification, quality control has great importance.
In tissue, in marrow, have a large amount of MSCs, but along with age ageing, the number of the MSCs in autologous bone marrow can significantly reduce and multiplication capacity also can significantly fail.Meanwhile, for guaranteeing autologous or donor safety, the acquisition technique of bone marrow MSCs is required strict, necessary instrument precision, cost are high, unsuitable application.Therefore, be more and more taken seriously with the research of external source for marrow.At present, different research is from perinatal placenta, umbilical cord, Cord blood, separates to obtain that multiplication capacity is good, the MSCs of reduced immunogenicity in the fat in liposuction source and aborted fetus.And in these tissues, umbilical cord belongs to Biohazard Waste, have be easy to obtain, steady sources is controlled, without the feature of dispute of ethic problem, there is good researching value and application prospect.
But, also there is no to realize preferably the primary separation of umbilical cord mesenchymal stem cells and method and the test kit of the amplification cultivation that goes down to posterity at present, this is one of this area problem demanding prompt solution.
Utility model content
For solving the problems of the technologies described above, the purpose of this utility model be to provide a kind of for separating of with cultivate umbilical cord mesenchymal stem cells (Umbilical cord mesenchymal stem cells, MSCs) test kit, this test kit comprises all ingredients and vessel, is convenient to separation and the cultivation of umbilical cord mesenchymal stem cells.
In order to achieve the above object, the utility model provide a kind of for separating of with cultivate the test kit of umbilical cord mesenchymal stem cells, it is characterized in that, should, for separating of comprising a box body with the test kit of cultivating umbilical cord mesenchymal stem cells, in this box body, at least be provided with damping fluid rest area, gelatin rest area, substratum rest area.
Above-mentioned for separating of with cultivate in the test kit of umbilical cord mesenchymal stem cells, preferably, described damping fluid rest area is provided with the first damping fluid bottle.
Above-mentioned for separating of with cultivate in the test kit of umbilical cord mesenchymal stem cells, preferably, described gelatin rest area is provided with the container of splendid attire gelatin.
Above-mentioned for separating of with cultivate in the test kit of umbilical cord mesenchymal stem cells, preferably, described substratum rest area is provided with the first wide-necked bottle.This first wide-necked bottle for example, for splendid attire substratum, BPS-SFM serum free medium.
Above-mentioned for separating of with cultivate in the test kit of umbilical cord mesenchymal stem cells, preferably, in described box body, be also provided with enzyme rest area and physiological saline rest area.
Above-mentioned for separating of with cultivate in the test kit of umbilical cord mesenchymal stem cells, preferably, described enzyme rest area is provided with brown Plastic Bottle and transparent wide-necked bottle.Brown Plastic Bottle is for the mixed solution of splendid attire Collagenase A or Collagenase A and neutral protease.Transparent wide-necked bottle is for splendid attire pancreatin.
Above-mentioned for separating of with cultivate in the test kit of umbilical cord mesenchymal stem cells, preferably, described physiological saline rest area is provided with the second wide-necked bottle.This second wide-necked bottle is for splendid attire physiological saline.
Above-mentioned for separating of with cultivate in the test kit of umbilical cord mesenchymal stem cells, preferably, described damping fluid rest area is provided with the second damping fluid bottle.This second damping fluid bottle is for splendid attire PBS damping fluid, for example, containing penicillin-Streptomycin sulphate and without Ca
2+, Mg
2+pBS damping fluid.
The mentioned reagent box that the utility model provides can carry out according to following steps separation and the cultivation of umbilical cord mesenchymal stem cells:
Take out the first damping fluid bottle of splendid attire PBS damping fluid in damping fluid rest area, with the PBS damping fluid containing penicillin and Streptomycin sulphate, healthy neonatal umbilical cord tissue is fully cleaned, remove blood stains;
Umbilical cord scissors is become to the uniform segment of length, carry out mechanical process separation, blunt separation China Tong Shi glue is removed Umbilical artery and umbilical vein simultaneously; The magnificent Tong Shi glue of peeling off is evenly shredded, obtain magnificent Tong Shi glue tissue block;
The container that takes out splendid attire gelatin, utilizes gelatin to spread quilt to culture dish, by the resuspended magnificent Tong Shi glue tissue block shredding of substratum, is inoculated in the culture dish of gelatin paving quilt, is placed in CO
2incubator is cultivated, and then centrifugation obtains tissue block and the resuspended liquid of cell.
When the mentioned reagent box providing when the utility model comprises enzyme rest area and physiological saline rest area, can carry out according to following steps separation and the cultivation of umbilical cord mesenchymal stem cells:
(1) the first damping fluid bottle of splendid attire PBS damping fluid in taking-up damping fluid rest area, fully clean by healthy neonatal umbilical cord tissue with the PBS damping fluid containing penicillin and Streptomycin sulphate, removal blood stains;
(2) umbilical cord scissors is become to the uniform segment of length, carry out mechanical process separation, blunt separation China Tong Shi glue is removed Umbilical artery and umbilical vein simultaneously; The magnificent Tong Shi glue of peeling off is evenly shredded;
Take out brown Plastic Bottle, to the mixed solution that adds Collagenase A or Collagenase A and neutral protease in the magnificent Tong Shi glue shredding, be placed in CO
2digestion process in incubator;
(3) after digestion process, carry out centrifugal treating collecting cell and remnant tissue, utilize PBS damping fluid to wash away residual enzyme, again carry out centrifugation, discard supernatant liquid;
(4) take out transparent wide-necked bottle and the second wide-necked bottle, in the residuum discarding after supernatant liquid, add pancreatin, be placed in CO
2digestion process in incubator, adds physiological saline to mix, and centrifugation, discards supernatant liquid;
(5) take out the first wide-necked bottle of splendid attire serum free medium and the container of splendid attire gelatin, utilize gelatin to spread quilt to culture dish, with the resuspended tissue of MSCs substratum and cell, be inoculated in the culture dish of gelatin paving quilt, be placed in CO
2incubator is cultivated, and then centrifugation obtains tissue block and the resuspended liquid of cell.
When the mentioned reagent box providing when the utility model comprises the container of splendid attire gelatin and the second damping fluid bottle, can carry out according to following steps separation and the cultivation of umbilical cord mesenchymal stem cells:
(1) the first damping fluid bottle of splendid attire PBS damping fluid in taking-up damping fluid rest area, fully clean by healthy neonatal umbilical cord tissue with the PBS damping fluid containing penicillin and Streptomycin sulphate, removal blood stains;
(2) umbilical cord scissors is become to the uniform segment of length, carry out mechanical process separation, blunt separation China Tong Shi glue is removed Umbilical artery and umbilical vein simultaneously; The magnificent Tong Shi glue of peeling off is evenly shredded;
Take out brown Plastic Bottle, to the mixed solution that adds Collagenase A or Collagenase A and neutral protease in the magnificent Tong Shi glue shredding, be placed in CO
2digestion process in incubator;
(3) after digestion process, carry out centrifugal treating collecting cell and remnant tissue, utilize PBS damping fluid to wash away residual enzyme, again carry out centrifugation, discard supernatant liquid;
(4) take out transparent wide-necked bottle and the second wide-necked bottle, in the residuum discarding after supernatant liquid, add pancreatin, be placed in CO
2digestion process in incubator, adds physiological saline to mix, and centrifugation, discards supernatant liquid;
(5) take out the first wide-necked bottle of splendid attire serum free medium and the container of splendid attire gelatin, utilize gelatin to spread quilt to culture dish, with the resuspended tissue of MSCs substratum and cell, be inoculated in the culture dish of gelatin paving quilt, be placed in CO
2incubator is cultivated, and then centrifugation obtains tissue block and the resuspended liquid of cell;
(6) take out the second damping fluid bottle, adopt gelatin to be coated with processing to a new culture dish, before inoculating cell, discard gelatin, use without Ca
2+, Mg
2+pBS damping fluid wash;
(7) be inoculated in step (6) culture dish after treatment separating the tissue block and the resuspended liquid of cell that obtain, in the time that Growth of Cells merges to 80%-90%, carry out had digestive transfer culture.
In above-mentioned steps (6), can adopt the gelatin of 0.1%-0.2% to be coated with culture dish, then at 37 ℃, 5%CO
2incubator in hatch and hatch 8-12 hour in 1 hour or 4 ℃.
Adopt test kit provided by the utility model can realize separation and the cultivation of umbilical cord mesenchymal stem cells, there is feature simple in structure, easy to use, contribute to the high purity and the high efficiency separation that realize umbilical cord mesenchymal stem cells to cultivate.
Accompanying drawing explanation
Fig. 1 for embodiment 1 provide for separating of with the structural representation of test kit of cultivating umbilical cord mesenchymal stem cells;
Fig. 2 for embodiment 2 provide for separating of with the structural representation of test kit of cultivating umbilical cord mesenchymal stem cells;
Fig. 3 for embodiment 3 provide for separating of with the structural representation of test kit of cultivating umbilical cord mesenchymal stem cells.
Main drawing reference numeral explanation:
The transparent wide-necked bottle 11 second wide-necked bottle 12 second damping fluid bottles 13 of the container 7 enzyme rest area 8 brown Plastic Bottle 10 in physiological saline rest area 9 of box body 1 damping fluid rest area 2 substratum rest area 3 gelatin rest area 4 first damping fluid bottle 5 first wide-necked bottle 6 splendid attire gelatin
Embodiment
Understand for technical characterictic of the present utility model, object and beneficial effect being had more clearly, existing the technical solution of the utility model is carried out to following detailed description, but can not be interpreted as restriction that can practical range of the present utility model.
The present embodiment provide a kind of for separating of with cultivate the test kit of umbilical cord mesenchymal stem cells, its structure is as shown in Figure 1.This test kit comprises a box body 1, is provided with damping fluid rest area 2, substratum rest area 3, gelatin rest area 4 in this box body 1, wherein:
In damping fluid rest area 2, be provided with the first damping fluid bottle 5, this first damping fluid bottle 5 is loaded with the PBS damping fluid of 2wt% penicillin-Streptomycin sulphate (penicillin final concentration 100U/mL, Streptomycin sulphate final concentration 0.01g/100mL);
Mentioned reagent box can carry out according to following steps separation and the cultivation of umbilical cord mesenchymal stem cells:
1, obtain 15cm healthy newborn umbilical cord tissue, fully clean with the PBS damping fluid containing 2wt% penicillin-Streptomycin sulphate (penicillin final concentration 100U/mL, Streptomycin sulphate final concentration 0.01g/100mL) in the first damping fluid bottle 5, fully remove blood stains;
2, clean umbilical cord is evenly cut to the segment into 3-4cm length, carry out mechanical process separation, blunt separation China Tong Shi glue is removed Umbilical artery and umbilical vein simultaneously, utilizes eye scissors that the magnificent Tong Shi glue of peeling off is cut as 1mm
3-3mm
3fritter, obtain magnificent Tong Shi glue tissue block;
3, get the container 7 of 10cm culture dish and splendid attire gelatin, culture dish is coated with the gelatin that concentration is 0.2wt%, be placed in 37 ℃, 5%CO
2incubator in hatch 1 hour, use without Ca
2+, Mg
2+pBS damping fluid wash, remove residual gelatin;
4, with the resuspended tissue of BPS-SFM serum free medium in the first wide-necked bottle 6 and cell (the magnificent Tong Shi glue tissue block shredding), be inoculated in the culture dish of gelatin paving quilt, be placed in 37 ℃, 5%CO
2the cultivation of incubator, merges and carries out had digestive transfer culture to 85% time until Growth of Cells.
Table 1
| Component | Content |
| α-MEM | 10.2g/L |
| Sodium bicarbonate | 2.4g/L |
| L-glutaminate | 5mM |
| PLURONICS F87 | 100mg/L |
| RHA | 8g/L |
| Recombinant human Transferrins,iron complexes | 20mg/L |
| Recombinant human insulin | 10mg/L |
| Hepes | 5mM |
| Beta-mercaptoethanol | 50nM |
| Cholesterol | 0.5mM |
| Arachidonic acid | 50nM |
| Palmitinic acid | 0.26mg/L |
| Zoomeric acid | 0.25mg/L |
| Stearic acid | 0.28mg/L |
| Oleic acid | 0.28mg/L |
| Linolic acid | 0.28mg/L |
| Linolenic acid | 0.28mg/L |
| Vitamin PP | 50mg/L |
| Vitamins C | 20mg/L |
| Cu | 5nM |
| Se | 30nM |
| Zn | 1mM |
| Ga | 0.3mM |
| Cr | 5μM |
| Mg | 0.3mM |
| Mn | 5nM |
| Gsh | 1mg/L |
| Para-amino benzoic acid | 1mg/L |
| Hydrocortisone | 50ng/mL |
| Compound shown in formula I | 10μM |
| Compound shown in formula II | 20μM |
| Progesterone | 15ng/mL |
| Putrescine | 10mg/L |
| Heparin | 10IU/mL |
| EGF | 10ng/mL |
| b-FGF | 10ng/mL |
| HGF | 10ng/mL |
| VEGF | 10ng/mL |
| Protocatechuic Acid | 1.5mmol/L |
| PDGF-BB | 10ng/mL |
| IGF-I | 10ng/mL |
| GM-CSF | 10ng/mL |
| TGF-β | 10ng/mL |
| α-MEM | 10.2g/L |
| Sodium bicarbonate | 2.4g/L |
| L-glutaminate | 5mM |
Above-mentioned BPS-SFM substratum is that water-fast composition can first be dissolved in suitable solvent to be mixed with water again by the various compositions shown in table 1 and water for injection are mixed and then adopts the filter filtration sterilization of 0.22 μ m to obtain.This BPS-SFM substratum should seal, and 4 ℃ keep in Dark Place.The cell culture reagent using for Sciencell company product, cytokine be the product of Peprotech company of the U.S., Tissue Culture Flask provides for German SARSTEDT company.
The various parameters of above-mentioned BPS-SFM substratum are as follows:
PH:7.2-7.4; Osmotic pressure: 260-320mOsm/kg; Bacterium, fungi detect: feminine gender; Chlamydozoan, detection of mycoplasma: feminine gender; Intracellular toxin <0.5EU/mL.
The present embodiment provide a kind of for separating of with cultivate the test kit of umbilical cord mesenchymal stem cells, its structure is as shown in Figure 2.This test kit comprises a box body 1, is provided with damping fluid rest area 2, substratum rest area 3, gelatin rest area 4, enzyme rest area 8 and physiological saline rest area 9 in this box body 1, wherein:
In damping fluid rest area 2, be provided with the first damping fluid bottle 5, this first damping fluid bottle 5 is loaded with the PBS damping fluid of 2wt% penicillin-Streptomycin sulphate (penicillin final concentration 100U/mL, Streptomycin sulphate final concentration 0.01g/100mL);
Physiological saline rest area 9 is provided with the second wide-necked bottle 12 of splendid attire physiological saline.
The present embodiment provide a kind of for separating of with cultivate the test kit of umbilical cord mesenchymal stem cells, its structure is as shown in Figure 3.The structure of this test kit is similar to the test kit of embodiment 2, and being has only increased by a second damping fluid bottle 13 in damping fluid rest area 2.
Mentioned reagent box can carry out according to following steps separation and the cultivation of umbilical cord mesenchymal stem cells:
1, obtain 10cm c-section neonatal umbilical cord tissue, with the PBS damping fluid containing 5wt% penicillin-Streptomycin sulphate (penicillin final concentration 100U/mL, Streptomycin sulphate final concentration 0.01g/100mL) in the first damping fluid bottle 5, fully remove blood stains;
2, clean umbilical cord is evenly cut as 3-4cm length segment, carried out mechanical process separation, blunt separation China Tong Shi glue is removed Umbilical artery and umbilical vein simultaneously;
3, the magnificent Tong Shi glue of peeling off is shredded as 1mm
3-3mm
3fritter, add the mixed solution (volume ratio of the two is 1:2) of the neutral protease that Collagenase A that the concentration of 15mL splendid attire in brown Plastic Bottle 10 is 1mg/mL and concentration are 1mg/mL, be placed in 37 ℃, 5%CO
2incubator in digestion process 2 hours, within every 20 minutes during this time, take out the digestion situation that detects;
4, after digestion process, centrifugal collecting cell and remnant tissue, utilize in physiological saline the second damping fluid bottle 13 in the second wide-necked bottle 12 containing penicillin-Streptomycin sulphate of 1wt% and without Ca
2+, Mg
2+pBS damping fluid (penicillin final concentration 100U/mL) wash away residual enzyme, with the rotating speed of 2000rpm centrifugal 5 minutes, abandon supernatant;
5, add the pancreatin that the concentration of 15mL splendid attire in transparent wide-necked bottle 11 is 0.25wt% (containing 0.02%EDTA), be placed in 37 ℃, 5%CO
2incubator in digest 10 minutes, every 3 minutes during this time monitoring digestion situations; After digestion process, utilize in the second damping fluid bottle 13 containing 1wt% penicillin-Streptomycin sulphate and without Ca
2+, Mg
2+pBS damping fluid wash away residual enzyme, with the rotating speed of 2000rpm centrifugal 5 minutes, abandon supernatant;
6, get the container of 10cm culture dish and splendid attire gelatin, culture dish is coated with the gelatin that concentration is 0.1wt%, 4 ℃ are spent the night, utilize in the second damping fluid bottle 13 without Ca
2+, Mg
2+pBS damping fluid wash, remove residual gelatin;
7, with the BPS-SFM serum free medium in the first wide-necked bottle 6 (with embodiment 1) resuspended tissue and cell, be inoculated in the culture dish of gelatin paving quilt, be placed in 37 ℃, 5%CO
2the cultivation of incubator, merges and carries out had digestive transfer culture to 85% time until Growth of Cells.
In BPS-SFM serum free medium, P0 is the short fusiformis growth of homogeneous for MSCs, and light transmission is good.
Claims (9)
- One kind for separating of with cultivate the test kit of umbilical cord mesenchymal stem cells, it is characterized in that, should, for separating of comprising a box body with the test kit of cultivating umbilical cord mesenchymal stem cells, in this box body, at least be provided with damping fluid rest area, gelatin rest area, substratum rest area.
- According to claim 1 for separating of with cultivate the test kit of umbilical cord mesenchymal stem cells, it is characterized in that, described damping fluid rest area is provided with the first damping fluid bottle.
- According to claim 1 for separating of with cultivate the test kit of umbilical cord mesenchymal stem cells, it is characterized in that, described gelatin rest area is provided with the container of splendid attire gelatin.
- According to claim 1 for separating of with cultivate the test kit of umbilical cord mesenchymal stem cells, it is characterized in that, described substratum rest area is provided with the first wide-necked bottle.
- According to claim 1 for separating of with cultivate the test kit of umbilical cord mesenchymal stem cells, it is characterized in that, in described box body, be also provided with enzyme rest area and physiological saline rest area.
- According to claim 5 for separating of with cultivate the test kit of umbilical cord mesenchymal stem cells, it is characterized in that, described enzyme rest area is provided with brown Plastic Bottle and transparent wide-necked bottle.
- According to claim 5 for separating of with cultivate the test kit of umbilical cord mesenchymal stem cells, it is characterized in that, described physiological saline rest area is provided with the second wide-necked bottle.
- According to claim 1 for separating of with cultivate the test kit of umbilical cord mesenchymal stem cells, it is characterized in that, described damping fluid rest area is provided with the second damping fluid bottle.
- According to claim 2 for separating of with cultivate the test kit of umbilical cord mesenchymal stem cells, it is characterized in that, described damping fluid rest area is provided with the second damping fluid bottle.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201320735171.XU CN203625386U (en) | 2013-08-16 | 2013-11-19 | Kit for separating and culturing umbilical cord mesenchymal stem cells |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201320500028 | 2013-08-16 | ||
| CN201320500028.2 | 2013-08-16 | ||
| CN201320735171.XU CN203625386U (en) | 2013-08-16 | 2013-11-19 | Kit for separating and culturing umbilical cord mesenchymal stem cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN203625386U true CN203625386U (en) | 2014-06-04 |
Family
ID=50811879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201320735171.XU Expired - Lifetime CN203625386U (en) | 2013-08-16 | 2013-11-19 | Kit for separating and culturing umbilical cord mesenchymal stem cells |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN203625386U (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107034184A (en) * | 2017-05-04 | 2017-08-11 | 济南赛尔生物科技股份有限公司 | A kind of kit for original cuiture umbilical cord mesenchymal stem cells |
| CN110684726A (en) * | 2018-07-06 | 2020-01-14 | 上海中溢精准医疗科技有限公司 | Method for separating and culturing umbilical cord mesenchymal stem cells |
| CN111621474A (en) * | 2019-02-28 | 2020-09-04 | 京东方科技集团股份有限公司 | Mesenchymal stem cell membrane and preparation method thereof |
-
2013
- 2013-11-19 CN CN201320735171.XU patent/CN203625386U/en not_active Expired - Lifetime
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107034184A (en) * | 2017-05-04 | 2017-08-11 | 济南赛尔生物科技股份有限公司 | A kind of kit for original cuiture umbilical cord mesenchymal stem cells |
| CN110684726A (en) * | 2018-07-06 | 2020-01-14 | 上海中溢精准医疗科技有限公司 | Method for separating and culturing umbilical cord mesenchymal stem cells |
| CN111621474A (en) * | 2019-02-28 | 2020-09-04 | 京东方科技集团股份有限公司 | Mesenchymal stem cell membrane and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103589683B (en) | Separation method and culture method for umbilical cord mesenchymal stem cells | |
| Watson et al. | Discarded Wharton jelly of the human umbilical cord: a viable source for mesenchymal stromal cells | |
| EP2422622B1 (en) | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions | |
| AU2010244047B2 (en) | Methods and apparatuses for isolating and preparing stem cells | |
| Mojallal et al. | Influence of negative pressure when harvesting adipose tissue on cell yield of the stromal–vascular fraction | |
| US20090269315A1 (en) | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions | |
| CN105062959A (en) | Isolated culture method of human amnia mesenchymal stem cells | |
| CN105820998A (en) | Isolation extraction and culture method for human adipose-derived stem cells (ADSCs) for clinical back-transfusion grade cell therapy | |
| CN113564111B (en) | Method for culturing umbilical cord-derived mesenchymal stem cells in low-oxygen mode | |
| CN106038598A (en) | Method for preparing human-derived stem cell secretion bioactive factor and lysate | |
| CN110564682A (en) | Method for large-scale production of human adipose-derived mesenchymal stem cell exosomes | |
| CN107460158A (en) | A kind of inducing umbilical cord mesenchymal stem is divided into the method to form insulin | |
| CN105663168A (en) | Cell preparation for repairing ovarian functions | |
| CN102965337A (en) | Method for separating and extracting human subcutaneous adipose-derived mesenchymal stem cells and special culture medium for extraction | |
| CN203625386U (en) | Kit for separating and culturing umbilical cord mesenchymal stem cells | |
| CN104762256A (en) | Method for extracting mesenchymal stem cells from umbilical cord Wharton's jelly | |
| Jiang et al. | Decellularized adipose tissue: A key factor in promoting fat regeneration by recruiting and inducing mesenchymal stem cells | |
| US9956317B2 (en) | Clinical applications of formulations containing adipose-derived stem cells | |
| CN106701670A (en) | Methods for enhancing bioactive factor secretion capacity of mesenchymal stem cells and extracting active factors in culture solution | |
| US11186828B2 (en) | Method of making human cells expressing OCT4, SOX2, and Nanog using an Ecklonia cava extract | |
| CN109355257B (en) | Mixed culture method of mesenchymal stem cells from different tissue sources | |
| ZA200507446B (en) | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions | |
| US20160130557A1 (en) | Formulations Containing and Kit for Using Adipose-Derived Stem Cells and Use Thereof | |
| Mannerström et al. | 3.1 Sources of Cells for Tissue Engineering Strategies | |
| JP6654323B2 (en) | Cells capable of forming stratified epithelial tissue and method for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20140604 |
|
| CX01 | Expiry of patent term |